Abstract c-Myc, a key activator of cell proliferation and angiogenesis, promotes the development and progression of breast cancer. Ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50) is a multifunctional scaffold protein that suppresses the proliferation of breast cancer cells. In this study we investigated whether the cancer-suppressing effects of EBP50 resulted from its regulation of c-Myc signaling in human breast cancer MCF-7 cells in vitro and in vivo c-Myc expression levels in breast cancer tissue, and demonstrated that EBP50 suppressed cell proliferation through decreasing the expression of c-Myc and its downstream proteins cyclin A, E and Cdc25A in MCF-7 cells. We further showed that EBP50 did not regulate c-Myc mRNA expression, but it promoted the degradation of c-Myc through the autophagic lysosomal pathway. Moreover, EBP50 promoted integration between c-Myc and p62, an autophagic cargo protein, triggering the autophagic lysosomal degradation of c-Myc. In EBP50-silenced MCF-7 cells, activation of autophagy by Beclin-1 promoted the degradation of c-Myc and inhibited cell proliferation. These results demonstrate that the EBP50/Beclin-1/p62/c-Myc signaling pathway plays a role in the proliferation in MCF-7 breast cancer cells: EBP50 stimulates the autophagic lysosomal degradation of c-Myc, thereby inhibits the proliferation of MCF-7 cells. Based on our results, promoting the lysosomal degradation of c-Myc might be a promising new strategy for treating breast cancer.
Introduction
Ezrin-radixin-moesin (ERM)-binding phosphoprotein-50 (EBP50) belongs to the Na + /H + exchanger regulatory factor (NHERF) family. Members of this family typically contain two PDZ domains and a unique C-terminal domain, and act as multifunctional scaffold proteins to regulate cellular activities. EBP50 has multiple functions, including acting as a signaling molecule, junction protein, receptor, and transporter, and many are involved in cancer signaling [1, 2] . EBP50 suppresses the proliferation of MDA-MB-231 breast cancer cells [3] , whereas EBP50 knockdown induces the growth of both MCF-7 and T47D cells [4] . Therefore, EBP50 has potential cancer-suppressive effects in breast cancer. However, the precise regulatory mechanism and signaling pathway used by EBP50 to regulate the proliferation of breast cancer cells remain unknown.
c-Myc is a key activator of cell proliferation and angiogenesis and promotes the development and progression of breast cancer [5] . c-Myc transfers from cytoplasm to nucleus and later promotes cell cycle by activating the transcription progression of downstream molecules such as cyclin A1, cyclin E1, and cell division cycle 25 homolog A (Cdc25A) to drive cell proliferation [6, 7] . Moreover, c-Myc also promotes cell proliferation by up-regulating DNA synthesis [8] , transcription, mitochondrial biogenesis and protein biosynthesis [9] . Previously, we found that EBP50 increases the expression of PTEN in breast cancer cells [2] and that loss of PTEN causes c-Myc-initiated carcinogenesis [10, 11] , which suggests that EBP50 might suppress cell proliferation by regulating c-Myc signaling in breast cancer cells.
In this study, we showed that EBP50 inhibits the proliferation of MCF-7 breast cancer cells by stimulating the autophagic lysosomal degradation of c-Myc. EBP50 suppresses cell proliferation by decreasing c-Myc expression as well as reducing the levels of c-Myc transcription products. Moreover, EBP50
promotes integration between c-Myc and p62, an autophagic cargo protein, to trigger autophagic lysosomal degradation of c-Myc. This activation of autophagy promotes the degradation of c-Myc and restrains cell proliferation in EBP50-silenced -nism used by EBP50 to suppress cancer cell proliferation and reveal a novel signaling pathway for EBP50-inhibited tumor proliferation in breast cancer.
Materials and methods
Reagents and antibodies CHX (01810), MG132 (C2211) and anti-SQSTM1 (P0067) antibodies were obtained from Sigma. Anti-human EBP50 (3394), c-Myc (13987), Cdc25A (3652), Cyclin E1 (20808), HA (3724), obtained from Cell Signaling Technology. Cyclin A1 (ab53699) was purchased from Abcam. c-Myc siRNA (sc-29226) and control siRNA (sc-37007) were purchased from Santa Cruz Biotechnology. Other materials were purchased from commercial sources.
Plasmid construction
The EBP50-shRNA-targeting sequence (5'-CACCGAC-CAGAAACGCAGCAGCAAACTTCAAGAGAGTTTGCT-GCTGCGTTTCTGGTTTTTTTG-3') was subcloned into the pRS shRNA cloning plasmid (Origene, TR20003). A control shRNA oligonucleotide that did not match any known human coding cDNA was used as a control. HA-tagged Beclin-1 (Gene Bank ID: NM_003766.3) was constructed in the pCMV6-AC-HA vector (Origene, PS100004) by standard subcloning. Myc-tagged EBP50 (Gene Bank ID: NM_004252.4) was created in the pCMV6-AN-Myc vector (Origene, PS100012) by standard subcloning.
Cell culture and transfection MCF-7 breast cancer cell lines were purchased from American Type Culture Collection (ATCC) and maintained as described [2] . Transient transfection was performed using Lipofectamine2000 (Invitrogen, 11668019) according to the manufacturer's instructions. To generate MCF-7 cells stably expressing EBP50 shRNA, the control-shRNA and EBP50-shRNA plasmids were both transfected into MCF-7 cells. After 24 h of transfection, stable transfectants were selected using purotechnique. To generate MCF-7 cells stably expressing Myctagged EBP50, the pCMV6-AN-Myc vector and Myc-tagged EBP50 plasmids were both transfected into MCF-7 cells. After 24 h of transfection, stable transfectants were selected using neomycin, and a single clone was amplified by a dilution cloning technique. To generate MCF-7 cells stably expressing Beclin-1, the Beclin-1 lentiviral activation particles (Santa Cruz Biotechnology, sc-400139-LAC) and control lentiviral particles were transfected into MCF-7 cells as described in the manual. To generate MCF-7 cells knockout c-Myc, the c-Myc CRISPR/ Cas9 KO plasmid (Santa Cruz Biotechnology, sc-400001) and control plasmid were transfected into MCF-7 cells as described in the manual.
Tissue microarray slides and immunohistochemistry
In vivo EBP50 or c-Myc expression was detected by immunohistochemistry (IHC) using tissue microarrays (US Biomax, BC081116c), which contained 110 HCC tissue specimens. IHC was performed according to standard protocols as described previously [12] .
Analysis of tumor growth
The female BALB/C nude mice (18±1 g) were obtained from the SPF Biotechology, Co Ltd (Beijing, China). The care and treatment of experimental animals was in accordance with institutional guidelines at the Experimental Animal Center of the Chinese Academy of Medical Sciences. As described previously [13] , the MCF-7 cells were injected subcutaneously (10 7 cells/tumor) into the left axilla of nude mice (n=8 per group). Mice were weighed, and tumor width (W) and length (L) were measured by vernier calipers every day. Tumor volume was estimated based on formula: V=0.5×L×W 
Colony formation assay
The MCF-7 cells stably expressing EBP50 shRNA or the control-shRNA were seeded in 6-well plates at a density of 2×10 
Cell growth assays
The MCF-7 cells were seeded at a density of 2×10 4 cells per well in 24-well plates and the Sulforhodamine B (SRB) proliferation assay was performed to assess cell proliferation.
Immunoprecipitation and Western blot analysis Cells were washed 3 times with phosphate-buffered saline (Invitrogen, 10010023) and then harvested and the cell lysates were extracted in co-immunoprecipitation buffer [2] . The total cell lysates (5 mg of protein) were subjected to immunoprecipitation as previously described [2] . For the Western blot analysis, co-precipitates or total cell lysates were electrophoresed by SDS-PAGE and transferred to PVDF membranes (Millipore, ISEQ00010). The membranes were immunoblotted with the appropriate antibodies and then developed using a ProteinSimple FluorChem HD2 imaging system (ProteinSimple, CA, USA).
Real-time PCR
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, 15596026). Total RNA (100 ng) was detected by using a SYBR Green One-Step qRT-PCR Kit (Invitrogen, 11736059) as described in the manual. The following prim--AAAT-3' and 5'-CCAGAGGCGTACAGGGATAGCAC-3'; c-Myc, 5'-AATGAAAAGGCCCCCAAGGTAGTTATCC-3' and 5'-GTCGTTTCCGCAACAAGTCCTCTTC-3'; Cdc25A, 5'-AGATAGCAGTGAACCAGG-3' and 5'-TGCATCGGTTGT-CAAGG-3'; Cyclin A1, 5'-GAGAGGGAAACTGCAGCTCG-3' and 5'-AGGAGGATATATCTCTTCAT-3'; Cyclin E1, 5'-ATA-CAGACCCACAGAGACAG-3' and 5'-TGCCATCCA-CAGAAATACTT-3'.
EdU assay
Standard protocols for EdU (5-ethynyl-2'-deoxyuridine) assay to detect the active DNA synthesis were used as described in the manual (Invitrogen, C10340). Images were obtained using a Leica SP2 confocal microscope (Leica Microsystems, Exton, PA, USA) and analyzed with Leica confocal software.
Statistical analysis
Data are represented as the mean±SEM. The statistical analyses were performed using Student's t-test to compare 2 groups. The P -cant. All statistical analyses were performed using SPSS 17.0 software.
Results

EBP50 knockdown promotes cell proliferation and stimualtes c-Myc signaling in MCF-7 cells
To investigate how EBP50 blocks cell proliferation, the relationship between EBP50 and c-Myc expression was examined in human clinical breast cancer tissues. The results showed that EBP50 expression was lower in breast cancer higher grades of malignancy and the c-Myc expression was positive correlation with malignancy grade ( Figure 1A ). These EBP50 and c-Myc expression in breast cancer tissue. We further found that EBP50 knockdown promoted cell proliferation ( Figure 1B and 1C) and induced DNA synthesis ( Figure 1D and Supplementary Figure S1 ). The knockdown EBP50 also increased c-Myc expression ( Figure 1E ) and promoted c-Myc transfer from the cytoplasm to nucleus ( Figure 1F ). Moreover, silencing of EBP50 induced mRNA expression of Cdc25A, Cyclin E1 and Cyclin A1 ( Figure 1G ), all of which are transcription products regulated by c-Myc; the protein expression of these elements was also increased ( Figure 1H ). These data suggest that silencing of EBP50 stimulates c-Myc signaling, which in turn promotes the proliferation of MCF-7 cells. 
EBP50 promotes c-Myc degradation
Because silencing of EBP50 induced c-Myc expression and thus promoted the proliferation of breast cancer cells (Figure 1 and 2) , we further explored whether EBP50 regulated c-Myc expression by affecting its transcription or degradation. The results showed that c-Myc mRNA expression levels did not differ between EBP50-silenced cells and control cells ( Figure 3A ), but knockdown of EBP50 increased the expression of c-Myc ( Figure 3B ). Likewise, overexpression of EBP50 decreased the expression of c-Myc but did not affect levels of c-Myc mRNA ( Figure 3C and 3D) . Furthermore, knockdown of EBP50 increased c-Myc degradation in cycloheximide (CHX)-treated MCF-7 cells ( Figure 3E ). Under the same conditions, overexpression of EBP50 promoted c-Myc degradation ( Figure 3F ). Taken together, these results indicate that EBP50 promotes the degradation of c-Myc.
EBP50 promotes the lysosomal degradation of c-Myc
As cytosolic proteins are typically degraded by either the ubiquitin proteasome pathway or the autophagy-lysosomal pathway, we next investigated which pathway participates in EBP50-mediated degradation of c-Myc. Treatment with the -radation, whereas blockage of the lysosomal pathway using chloroquine (CQ) significantly attenuated c-Myc degradation in cells overexpressing EBP50 ( Figure 4A ). Above data suggested that EBP50 induced the lysosomal degradation of c-Myc. We previously reported that EBP50 activates autophagy by stimulating Beclin-1, which triggers the autophagic core complex [2] . Hence, we further examined whether EBP50-mediated lysosomal degradation of c-Myc was dependent on Beclin-1. Silencing of Beclin-1 delayed this degradation in cells overexpressing EBP50 ( Figure 4B ), and overexpression of Beclin-1 accelerated the degradation of c-Myc in sh-EBP50 cells ( Figure 4C ). These data suggest that EBP50 induces the lysosomal degradation of c-Myc by activating Beclin-1.
p62 recognizes c-Myc as a substrate of lysosomal degradation by binding to c-Myc p62/SQSTM1 (Sequestosome 1), an autophagic cargo protein, recognizes the substrates of lysosomal degradation by binding to them. Hence, we next investigated whether p62 binds to c-Myc. Co-immunoprecipitation and Glutathione S-transferase (GST) pull-down assays showed that p62 could bind to c-Myc both in vivo and in vitro ( Figure 5A and 5B). Additionally, silencing of EBP50 decreased the interaction between p62 and c-Myc ( Figure 5C ). Interestingly, overexpression of EBP50 also reduced the binding of p62 and c-Myc, and inhibiting autophagy using CQ promoted the interaction between p62 and c-Myc ( Figure 5D ). Furthermore, EBP50 promoted the integration of c-Myc and p62 when the lysosomal pathway was inhibited by CQ ( Figure 5E ). These data suggest that p62 Figure 4B and 4C) . Thus, we next explored whether EBP50 suppressed the proliferation of breast cancer cells following the stimulation of Beclin-1 expression. Overexpression of Beclin-1 suppressed colony formation ( Figure 6A and 6C) and DNA synthesis ( Figure 6B and 6D) in EBP50-knockdown cells, which suggests that EBP50-mediated suppression of MCF-7 cell proliferation depends on increased levels of Beclin-1. Furthermore, overexpression of Beclin-1 reduced the nuclear import of c-Myc ( Figure 6E ) and decreased the expression of transcription products regulated by c-Myc ( Figure 6F and 6G) , which suggests that stimulation of autophagy by the overexpression of Beclin-1 inhibits c-Mycrelated signaling. Together, these data suggest that EBP50 suppresses cell proliferation by stimulating Beclin-1-mediated lysosomal degradation of c-Myc in MCF-7 breast cancer cells. Figure 7D ). Together, these data suggested that EBP50 suppresses tumor proliferation by regulating Beclin-1/p62/c-Myc signal pathway ( Figure 7E ).
Discussion
Cytoplasmic EBP50 suppresses cell proliferation by regulating various signaling pathways in breast cancer cells. Overexpressing EBP50 decreased the tumor growth and silencing EBP50 increased it in MCF-7 cells (Figure 1 and Supplementary Figure S2 ). In MDA-MB-231 cells, EBP50 suppresses cell growth by promoting apoptosis [14] . EBP50 also inhibits epidermal growth factor (EGF)-induced breast cancer cell proliferation by blocking extracellular signal-regulated kinase 1 and 2 (ERK1/2) and Akt phosphorylation [3] . In our current study, we found that EBP50 inhibits the cell proliferation by suppressing c-Myc signaling in MCF-7 cells (Figure 2) . Our report suggests that EBP50 plays a significant role in suppressing c-Myc signaling to trigger the inhibition of tumor proliferation in MCF-7 cells.
In the development and progression of breast cancer, c-Myc transfers from cytoplasm to nucleus and later promotes the transcription progression on regulators of cell cycle, such as cyclin A1, cyclin E1, and Cdc25A, to drive cell proliferation [6, 7] . Hence, the nuclear c-Myc, not the cytoplasmic c-Myc, plays a pivotal role on cell proliferation. In our current studies, we observed that silencing EBP50 induced the expression of c-Myc in the whole cell lysates ( Figure 1E ). And we further found that silencing EBP50 increased the level of nuclear c-Myc ( Figure 1F ) and the expressions of downstream molecules (such as cyclin A1, cyclin E1 and Cdc25A) ( Figure 1H ), suggesting that silencing EBP50 stimulated the c-Myc signaling pathway. In previous studies, we found that overexpressing EBP50 stimulates autophagy and silencing EBP50 restrains it in cytoplasm [2] . In our current studies, we observed that silencing EBP50 delayed the autophagic lysosomal degradation of c-Myc (Figure 4 ), not affect the RNA level of c-Myc ( Figure 3A and 3C) . Together, these above observations suggested that silencing EBP50 blocked the autophagic lysosomal c-Myc degradation has been been shown to restrain cancer proliferation and various factors inhibit tumor growth by causing c-Myc degradation. Pim kinase, an oncogene important in leukemia, lymphoma, prostate and pancreatic cancer, stabilizes c-Myc and inhibits its degradation [15] . TM, a potent promoting c-Myc ubiquitination and degradation [16] . Gamabufotalin inhibits cell growth and induces apoptosis by evoking the ubiquitination and degradation of c-Myc in multiple myeloma cells [17] . The above studies suggest that stimulation of c-Myc degradation is effective for inhibiting tumor cell proliferation. However, the above reports focused only on ubiquitin-mediated degradation of c-Myc. In the present study, we showed that EBP50, an activator of autophagy, causes lysosomal degradation of c-Myc to suppress the growth of MCF-7 breast cancer cells (Figure 4 and 6) . Overall, the above findings suggest that c-Myc is degraded through both the lysosomal and ubiquitin pathway and that promoting c-Myc degradation inhibits tumor cell proliferation.
p62, an autophagic cargo protein, binds to endogenous autophagy substrates during autophagic lysosomal degradation. GATA4 acts as an activator of hepatoblastoma cell proliferation [18] ; after binding to p62, GATA4 is degraded through the autophagic lysosomal pathway [19] . Our results showed that p62 binds to c-Myc, causing c-Myc degradation through the lysosomal pathway ( Figure 5 ), which is consistent with the above report. Moreover, other autophagy-related proteins also regulate the degradation of c-Myc. Valentina et al found that the pro-autophagic protein AMBRA1 regulates cell proliferation by facilitating the degradation of c-Myc [20] , but they did not discuss AMBRA1 causes the degradation of c-Myc by ubiquitin proteasome pathway or the autophagy-lysosomal pathway. Pietri et al reported CIP2A, an inhibitor of autophagy by stimulating mammalian target of rapamycin complex 1 (mTORC1), protects c-Myc against proteasome-mediated degradation, which suggests there is a strong correlation between the activation on autophagy and degradation of c-Myc [21] . Luciana et al found that chaperone-mediated autophagy promotes c-Myc ubiquitination and degradation [22] and our by macroautophagic lysosomal pathway directly. The above studies focused on the proteasome-mediated degradation of c-Myc and did not explored the autophagic lysosomal degradation of c-Myc. Hence, our studies revealed a novel degradation pathway of c-Myc by macroautophagic lysosomal pathway. In summary, EBP50 up-regulates the lysosomal degradation of c-Myc and inhibits c-Myc-related signaling to suppress the -naling pathway and highlight the molecular mechanism used by EBP50 to mediate cancer cell proliferation. Based on our results, promoting the lysosomal degradation of c-Myc might
